OBJECTIVES: To determine the contribution of transmission clusters to transmitted drug resistance (TDR) in newly diagnosed antiretroviral-naive HIV-1-infected patients in Northern Greece during 2000-07. METHODS: The prevalence of TDR was estimated in 369 individuals who were diagnosed with HIV-1 infection in the period 2000-07 at the National AIDS Reference Laboratory of Northern Greece. Phylogenetic analysis was performed using a maximum likelihood method on partial pol sequences. TDR was defined in accordance with the surveillance drug resistance mutation list (2009 update). RESULTS: The overall prevalence of TDR in our population was 12.5% [46/369, 95% confidence interval (CI) 9.1%-15.8%], comprising 7.6% (28/369) resistant to nucleoside reverse transcriptase inhibitors, 5.4% (20/369) resistant to non-nucleoside reverse transcriptase inhibitors and 3.3% (12/369) resistant to protease inhibitors. Dual class resistance was identified in 3.8% (14/369). Infection with subtype A was the sole predictor associated with TDR in multivariate analysis (odds ratio 2.15, 95% CI 1.10-4.19, P = 0.025). Phylogenetic analyses revealed three statistically robust transmission clusters involving drug-resistant strains, including one cluster of 12 patients, 10 of whom were infected with a strain carrying both T215 revertants and Y181C mutations. CONCLUSIONS: Our findings underline the substantial impact of transmission networks on TDR in our population.
OBJECTIVES: To determine the contribution of transmission clusters to transmitted drug resistance (TDR) in newly diagnosed antiretroviral-naive HIV-1-infectedpatients in Northern Greece during 2000-07. METHODS: The prevalence of TDR was estimated in 369 individuals who were diagnosed with HIV-1 infection in the period 2000-07 at the National AIDS Reference Laboratory of Northern Greece. Phylogenetic analysis was performed using a maximum likelihood method on partial pol sequences. TDR was defined in accordance with the surveillance drug resistance mutation list (2009 update). RESULTS: The overall prevalence of TDR in our population was 12.5% [46/369, 95% confidence interval (CI) 9.1%-15.8%], comprising 7.6% (28/369) resistant to nucleoside reverse transcriptase inhibitors, 5.4% (20/369) resistant to non-nucleoside reverse transcriptase inhibitors and 3.3% (12/369) resistant to protease inhibitors. Dual class resistance was identified in 3.8% (14/369). Infection with subtype A was the sole predictor associated with TDR in multivariate analysis (odds ratio 2.15, 95% CI 1.10-4.19, P = 0.025). Phylogenetic analyses revealed three statistically robust transmission clusters involving drug-resistant strains, including one cluster of 12 patients, 10 of whom were infected with a strain carrying both T215 revertants and Y181C mutations. CONCLUSIONS: Our findings underline the substantial impact of transmission networks on TDR in our population.
Authors: Dana K Pasquale; Irene A Doherty; Lynne A Sampson; Stephane Hué; Peter A Leone; Joseph Sebastian; Sue L Ledford; Joseph J Eron; William C Miller; Ann M Dennis Journal: J Acquir Immune Defic Syndr Date: 2018-08-01 Impact factor: 3.731
Authors: Lisa L Ross; Joseph Horton; Samiul Hasan; James R Brown; Daniel Murphy; Edwin DeJesus; Martin Potter; Anthony LaMarca; Ivan Melendez-Rivera; Douglas Ward; Jonathon Uy; Mark S Shaefer Journal: PLoS One Date: 2014-02-26 Impact factor: 3.240
Authors: Andrea-Clemencia Pineda-Peña; Yoeri Schrooten; Lore Vinken; Fossie Ferreira; Guangdi Li; Nídia Sequeira Trovão; Ricardo Khouri; Inge Derdelinckx; Paul De Munter; Claudia Kücherer; Leondios G Kostrikis; Claus Nielsen; Kirsi Littsola; Annemarie Wensing; Maja Stanojevic; Roger Paredes; Claudia Balotta; Jan Albert; Charles Boucher; Arley Gomez-Lopez; Eric Van Wijngaerden; Marc Van Ranst; Jurgen Vercauteren; Anne-Mieke Vandamme; Kristel Van Laethem Journal: PLoS One Date: 2014-07-08 Impact factor: 3.240